Ian Churcher

Ian Churcher

Company: Amphista Therapeutics

Job title: CSO


New Approaches to Degradation – Beyond the Usual Suspects 9:00 am

Amphista Therapeutics uses a completely novel range of mechanisms to degrade a wide range of disease-relevant proteins Mechanisms go beyond the usual E3 ligases utilised by most in the field and instead use other UPS proteins which offer new opportunities to expand the scope and utility of TPD strategies We will discuss how novel mechanisms…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.